Viridian Therapeutics, Inc./DE Operating Cash Flow
Viridian Therapeutics, Inc./DE (VRDN) reported Operating Cash Flow of -$224.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$105.32M.
- Viridian Therapeutics, Inc./DE net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$119.65M.
- Viridian Therapeutics, Inc./DE net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$23.75M.
- Viridian Therapeutics, Inc./DE net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$84.61M.
- Viridian Therapeutics, Inc./DE net cash provided by (used in) operating activities for fiscal 2025 was -$276.39M.
- Viridian Therapeutics, Inc./DE net cash provided by (used in) operating activities for fiscal 2024 was -$232.32M.
- Viridian Therapeutics, Inc./DE net cash provided by (used in) operating activities for fiscal 2023 was -$184.17M.
- Viridian Therapeutics, Inc./DE net cash provided by (used in) operating activities for fiscal 2022 was -$93.84M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$105.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$224.98M 10-Q · filed 2026-08-06 | -$248.73M derived: sum of 3 quarters · filed 2026-08-06 | -$333.34M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$119.65M 10-Q · filed 2026-05-05 | -$143.41M derived: sum of 2 quarters · filed 2026-05-05 | -$228.02M derived: sum of 3 quarters · filed 2026-05-05 | -$303.39M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$23.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$108.36M derived: sum of 2 quarters · filed 2026-02-26 | -$183.74M derived: sum of 3 quarters · filed 2026-08-06 | -$276.39M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$84.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$159.98M derived: sum of 2 quarters · filed 2026-08-06 | -$252.64M 10-Q · filed 2025-11-05 | -$325.97M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$75.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$168.03M 10-Q · filed 2026-08-06 | -$241.36M derived: sum of 3 quarters · filed 2026-08-06 | -$309.06M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$92.65M 10-Q · filed 2026-05-05 | -$165.99M derived: sum of 2 quarters · filed 2026-05-05 | -$233.69M derived: sum of 3 quarters · filed 2026-05-05 | -$279.75M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$73.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$141.04M derived: sum of 2 quarters · filed 2026-02-26 | -$187.10M derived: sum of 3 quarters · filed 2026-02-26 | -$232.32M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$67.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$113.76M derived: sum of 2 quarters · filed 2025-11-05 | -$158.99M 10-Q · filed 2025-11-05 | -$196.99M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | -$46.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$91.28M 10-Q · filed 2025-08-06 | -$129.28M derived: sum of 3 quarters · filed 2026-02-26 | -$168.26M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | -$45.22M 10-Q · filed 2025-05-06 | -$83.22M derived: sum of 2 quarters · filed 2026-02-26 | -$122.21M derived: sum of 3 quarters · filed 2026-02-26 | -$167.42M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | -$38.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$76.98M derived: sum of 2 quarters · filed 2026-02-26 | -$122.20M derived: sum of 3 quarters · filed 2026-02-26 | -$184.17M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | -$38.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$84.20M derived: sum of 2 quarters · filed 2024-11-12 | -$146.17M 10-Q · filed 2024-11-12 | -$180.21M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | -$45.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$107.19M 10-Q · filed 2024-08-08 | -$141.23M derived: sum of 3 quarters · filed 2025-03-03 | -$161.90M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | -$61.97M 10-Q · filed 2024-05-08 | -$96.02M derived: sum of 2 quarters · filed 2025-03-03 | -$116.68M derived: sum of 3 quarters · filed 2025-03-03 | -$134.77M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | -$34.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$54.71M derived: sum of 2 quarters · filed 2025-03-03 | -$72.80M derived: sum of 3 quarters · filed 2025-03-03 | -$93.84M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | -$20.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$38.75M derived: sum of 2 quarters · filed 2023-11-13 | -$59.80M 10-Q · filed 2023-11-13 | -$76.33M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | -$18.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$39.13M 10-Q · filed 2023-08-08 | -$55.66M derived: sum of 3 quarters · filed 2024-02-27 | -$67.54M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | -$21.04M 10-Q · filed 2023-05-10 | -$37.58M derived: sum of 2 quarters · filed 2024-02-27 | -$49.45M derived: sum of 3 quarters · filed 2024-02-27 | -$64.08M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | -$16.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$28.41M derived: sum of 2 quarters · filed 2024-02-27 | -$43.04M derived: sum of 3 quarters · filed 2024-02-27 | -$54.58M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | -$11.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$26.51M derived: sum of 2 quarters · filed 2022-11-14 | -$38.05M 10-Q · filed 2022-11-14 | -$47.48M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | -$14.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$26.17M 10-Q · filed 2022-08-15 | -$35.61M derived: sum of 3 quarters · filed 2022-08-15 | -$40.70M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | -$11.54M 10-Q · filed 2022-05-13 | -$20.98M derived: sum of 2 quarters · filed 2022-05-13 | -$26.07M derived: sum of 3 quarters · filed 2022-05-13 | -$32.86M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | -$9.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$14.53M derived: sum of 2 quarters · filed 2022-03-11 | -$21.32M derived: sum of 3 quarters · filed 2022-03-11 | -$29.78M 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | -$5.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$11.88M derived: sum of 2 quarters · filed 2021-11-05 | -$20.34M 10-Q · filed 2021-11-05 | -$28.15M derived: sum of 4 quarters · filed 2021-11-05 | ||||
| 2020-06-30 | -$6.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$15.25M 10-Q · filed 2021-08-12 | -$23.05M derived: sum of 3 quarters · filed 2021-08-12 | -$32.32M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | -$8.46M 10-Q · filed 2021-05-07 | -$16.27M derived: sum of 2 quarters · filed 2021-05-07 | -$25.53M derived: sum of 3 quarters · filed 2021-05-07 | -$32.71M derived: sum of 4 quarters · filed 2021-05-07 | ||||
| 2019-12-31 | -$7.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | -$17.07M derived: sum of 2 quarters · filed 2021-03-26 | -$24.25M derived: sum of 3 quarters · filed 2021-03-26 | -$36.06M 10-K · filed 2021-03-26 | ||||
| 2019-09-30 | -$9.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$16.44M derived: sum of 2 quarters · filed 2020-11-12 | -$28.25M 10-Q · filed 2020-11-12 | -$36.42M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | -$7.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$18.98M 10-Q · filed 2020-08-05 | -$27.16M derived: sum of 3 quarters · filed 2020-08-05 | -$33.96M derived: sum of 4 quarters · filed 2020-08-05 | ||||
| 2019-03-31 | -$11.81M 10-Q · filed 2020-05-08 | -$19.98M derived: sum of 2 quarters · filed 2020-05-08 | -$26.79M derived: sum of 3 quarters · filed 2020-05-08 | -$31.29M derived: sum of 4 quarters · filed 2020-05-08 | ||||
| 2018-12-31 | -$8.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | -$14.98M derived: sum of 2 quarters · filed 2020-03-13 | -$19.48M derived: sum of 3 quarters · filed 2020-03-13 | -$26.84M 10-K · filed 2020-03-13 | ||||
| 2018-09-30 | -$6.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$11.31M derived: sum of 2 quarters · filed 2019-11-08 | -$18.67M 10-Q · filed 2019-11-08 | -$25.91M derived: sum of 4 quarters · filed 2019-11-08 | ||||
| 2018-06-30 | -$4.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$11.87M 10-Q · filed 2019-08-08 | -$19.11M derived: sum of 3 quarters · filed 2019-08-08 | -$24.77M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | -$7.36M 10-Q · filed 2019-05-09 | -$14.60M derived: sum of 2 quarters · filed 2019-05-09 | -$20.27M derived: sum of 3 quarters · filed 2019-05-09 | -$27.34M derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | -$7.24M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$12.91M derived: sum of 2 quarters · filed 2019-03-14 | -$19.98M derived: sum of 3 quarters · filed 2019-03-14 | -$28.17M 10-K · filed 2019-03-14 | ||||
| 2017-09-30 | -$5.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$12.74M derived: sum of 2 quarters · filed 2018-11-07 | -$20.92M 10-Q · filed 2018-11-07 | -$24.21M derived: sum of 4 quarters · filed 2018-11-07 | ||||
| 2017-06-30 | -$7.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$15.26M 10-Q · filed 2018-08-08 | -$18.55M derived: sum of 3 quarters · filed 2018-08-08 | -$21.38M derived: sum of 4 quarters · filed 2018-08-08 | ||||
| 2017-03-31 | -$8.18M 10-Q · filed 2018-05-09 | -$11.47M derived: sum of 2 quarters · filed 2018-05-09 | -$14.30M derived: sum of 3 quarters · filed 2018-05-09 | -$18.77M derived: sum of 4 quarters · filed 2018-05-09 | ||||
| 2016-12-31 | -$3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$6.12M derived: sum of 2 quarters · filed 2018-03-15 | -$10.59M derived: sum of 3 quarters · filed 2018-03-15 | -$14.76M 10-K · filed 2018-03-15 | -$7.23M 10-K · filed 2017-03-24 | |||
| 2016-09-30 | -$2.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$7.30M derived: sum of 2 quarters · filed 2017-11-09 | -$11.47M 10-Q · filed 2017-11-09 | -$5.35M 10-Q · filed 2016-10-26 | -$12.77M derived: sum of 4 quarters · filed 2017-11-09 | |||
| 2016-06-30 | -$4.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | -$8.63M 10-Q · filed 2017-08-11 | -$4.23M 10-Q · filed 2016-08-15 | -$9.93M derived: sum of 3 quarters · filed 2017-08-11 | -$12.24M derived: sum of 4 quarters · filed 2017-08-11 | |||
| 2016-03-31 | -$4.17M 10-Q · filed 2017-05-11 | -$2.22M 10-Q · filed 2016-05-16 | -$5.47M derived: sum of 2 quarters · filed 2017-05-11 | -$7.77M derived: sum of 3 quarters · filed 2017-05-11 | -$9.96M derived: sum of 4 quarters · filed 2017-05-11 | |||
| 2015-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | -$3.60M derived: sum of 2 quarters · filed 2017-03-24 | -$5.79M derived: sum of 3 quarters · filed 2017-03-24 | -$6.90M 10-K · filed 2017-03-24 | ||||
| 2015-09-30 | -$2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | -$4.49M derived: sum of 2 quarters · filed 2016-10-26 | -$5.60M 10-Q · filed 2016-10-26 | -$6.60M derived: sum of 4 quarters · filed 2016-10-26 | ||||
| 2015-06-30 | -$2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$3.29M 10-Q · filed 2016-08-15 | -$4.29M derived: sum of 3 quarters · filed 2016-08-15 | -$5.12M derived: sum of 4 quarters · filed 2016-08-15 | ||||
| 2015-03-31 | -$1.11M 10-Q · filed 2016-05-16 | -$2.11M derived: sum of 2 quarters · filed 2016-05-16 | -$2.94M derived: sum of 3 quarters · filed 2016-05-16 | -$3.41M derived: sum of 4 quarters · filed 2016-05-16 | ||||
| 2014-12-31 | -$997.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-21 | -$1.83M derived: sum of 2 quarters · filed 2016-03-21 | -$2.30M derived: sum of 3 quarters · filed 2016-03-21 | -$2.21M 10-K · filed 2016-03-21 | ||||
| 2014-09-30 | -$831.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | -$1.30M derived: sum of 2 quarters · filed 2015-11-13 | -$1.22M 10-Q · filed 2015-11-13 | -$1.22M 10-Q · filed 2014-11-14 | -$1.57M derived: sum of 4 quarters · filed 2015-11-13 | |||
| 2014-06-30 | -$470.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | -$385.00K 10-Q · filed 2015-08-14 | -$385.22K 10-Q · filed 2014-08-14 | -$742.75K derived: sum of 3 quarters · filed 2015-08-14 | -$1.04M derived: sum of 4 quarters · filed 2015-08-14 | |||
| 2014-03-31 | $85.00K 10-Q · filed 2015-05-15 | -$272.75K derived: sum of 2 quarters · filed 2015-05-15 | -$568.93K derived: sum of 3 quarters · filed 2015-05-15 | |||||
| 2013-12-31 | -$357.75K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | -$653.93K derived: sum of 2 quarters · filed 2015-03-27 | -$1.17M 10-K · filed 2015-03-27 | |||||
| 2013-09-30 | -$296.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | -$810.25K 10-Q · filed 2014-11-14 | ||||||
| 2013-06-30 | -$514.07K 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |